Phyrago Shortage Update: What Patients Need to Know in 2026

Patients with Philadelphia chromosome-positive (Ph+) leukemia who have been prescribed Phyrago (dasatinib) are frequently asking whether the drug is in shortage. The confusion is understandable — when you can't fill a prescription at your usual pharmacy, it feels like a shortage. But the reality of Phyrago's availability in 2026 is more nuanced.

Is There an Official Phyrago Shortage in 2026?

As of 2026, the FDA has not listed Phyrago on its official Drug Shortage Database. There is no manufacturer-reported supply disruption, no shortage alert from the American Society of Health-System Pharmacists (ASHP), and no known raw material or manufacturing issue affecting Phyrago's production.

However, Phyrago is a relatively new product — it was commercially launched in the United States in October 2025. As with many newly launched specialty oncology drugs, distribution infrastructure is still being built out, prescriber awareness is growing, and the specialty pharmacy access pathway is becoming more established for patients nationwide.

What Background Should I Know About Phyrago?

Phyrago is a novel formulation of dasatinib manufactured by Handa Therapeutics and commercialized in the US by Cycle Pharmaceuticals. Dasatinib itself has been approved since 2006 (as Sprycel from Bristol-Myers Squibb), so the active ingredient has a long clinical track record. Phyrago's key innovation is its ability to be taken concomitantly with proton pump inhibitors (PPIs) and H2 receptor antagonists — acid-suppressing medications that dramatically reduce the bioavailability of standard dasatinib formulations.

Why Does Phyrago Feel So Hard to Access?

The access challenges patients face with Phyrago come from three main sources:

1. Exclusive specialty pharmacy distribution. Phyrago is only available through Onco360 specialty pharmacy. You cannot fill it at any retail pharmacy nationwide.

2. Prior authorization requirements. Nearly all insurance plans require prior authorization for specialty tier oncology drugs. This process can take 3–14 business days and requires documentation from your oncologist.

3. Step therapy requirements. Some insurance plans require patients to try generic dasatinib first before authorizing brand-name Phyrago. Your oncologist may need to document why Phyrago is specifically necessary (e.g., you take a PPI or H2RA).

How Does Phyrago's Distribution Compare to Generic Dasatinib?

Generic dasatinib, while also a specialty drug, is available from multiple manufacturers and through a broader network of specialty pharmacies. If your insurance plan insists on step therapy through generic dasatinib first, generic dasatinib is more widely accessible in the short term. The key clinical difference remains: if you also take acid-reducing medications like omeprazole, pantoprazole, esomeprazole, or famotidine, generic dasatinib's effectiveness may be significantly reduced.

What Should Patients Do Right Now?

If you've been prescribed Phyrago and are experiencing access difficulties, take these steps:

• Enroll in Cycle Vita immediately — Call 888-360-8482 to start the access process. They can provide a free starter supply while insurance is being sorted out.

• Have your oncologist document your PPI/H2RA use — This is often the clinical justification needed to overcome step therapy requirements.

• Ask about appeals if prior authorization is denied — Your oncologist can file an urgent appeal if Phyrago is medically necessary. Most insurers must respond to urgent appeals within 72 hours.

• Check your state's external review process if your appeal is also denied.

What About the Broader Dasatinib Shortage History?

Generic dasatinib has at times been on the FDA shortage list historically. These shortages affected standard dasatinib (generic and Sprycel), not Phyrago specifically since Phyrago only launched in late 2025. If you or your provider are concerned about future supply disruptions, it's worth discussing your treatment options and backup plans with your oncology team.

For real-time pharmacy search assistance, visit medfinder.com. Also read our deeper explainer on why Phyrago is hard to find in 2026.